Hospital.Help

Silver Spring – For the first time, the US Food and Drug Administration (FDA) has approved a drug for the treatment of schizophrenia that does not bind directly to dopamine receptors. The drug Cobenfy (KarXT) combines the centrally acting selective muscarinic receptor agonist… [weiter lesen]

#Schizophrenia #FDA #approves #antipsychotic #extrapyramidal #side #effects